Akston Biosciences, a United States-based company that deals with insulin engineering, has collaborated with LakePharma, a United States-based CRDMO serving the biotechnology community, to produce commercial quantities of Akston's adjuvated COVID-19 vaccine candidate, AKS-452, it was reported on Tuesday.
The vaccine candidate is scheduled to commence phase 1/2 clinical testing later this month.
AKS-452 is a COVID-19-specific Fc fusion protein vaccine that is in commercial development and is designed to induce or boost a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain of the novel SARS-CoV-2 coronavirus spike protein. It is shelf-stable for weeks at up to 37 degrees Celsius and is engineered to use conventional antibody manufacturing techniques.
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder
WuXi AppTec's Nantong site receives 2025 Architizer A+Award
MGI partners with Negedia to enhance genomic sequencing in Italy
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator